In the same line, AL101 (osugacestat) has been shown to have potent antitumor effects in in vitro and in vivo models (AdCC cell lines, organoids, and patient-derived xenograft models) of AdCC with activating NOTCH1 mutations [58]. This evidence concerns the gene NOTCH1 and adrenocortical carcinoma, hereditary.